|
ANTAGONISE ANTIEPILEPTIC EFFECTS OF THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF VALPROIC ACID HAVE BEEN SEEN WHILE VALPROIC ACID INHIBITS CARBAMAZEPINE METABOLISM
|
CONCURRENT ADMINISTRATION CAN LEAD TO INCREASED INCIDENCE OF THROMBOCYTOPENIA & G I BLEEDING
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
CO-ADMINISTRATION RESULTS IN INCREASED AUC OF ZIDOVUDINE BY 80%-100%; ROUTINE DOSE MODIFICATION OF ZIDOVUDINE IS NOT WARRANTED UNLESS PT. IS EXPERIENCING PRONOUNCED ANEMIA OR OTHER SEVERE SIDE EFFECTS OF ZIDOVUDINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF VALPROATE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF VALPROATE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF VALPROATE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF VALPROATE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF VALPROATE
|
ACETAZOLAMIDE MAY ENHANCE ANTIEPILEPTIC INDUCED OSTEOMALACIA
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
VALPROIC ACID SERUM CONC. IS DECREASED RESULTING IN INCREASED RISK FOR BREAKTHROUGH SEIZURES
|
VALPROIC ACID SERUM CONC. IS DECREASED RESULTING IN INCREASED RISK FOR BREAKTHROUGH SEIZURES
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
VALPROIC ACID ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
VALPROIC ACID ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
VALPROIC ACID ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
FOLIC ACID DEFICIENCY MAY PRECIPITATE WITH CONCURRENT USE
|
INTERFERES WITH THE ACTION OF BOTH DRUGS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
VALPROATE DISPLACES PHENYTOIN FROM ITS SERUM BINDING SITE & MAY INHIBIT ITS METABOLISM LEADING TO INCREASED PLASMA CONC.
|
MEROPENEM REDUCE SERUM LEVELS OF THE DRUG TO SUBTHERAPEUTIC LEVELS
|
IT CAN INDUCE HYPERAMMONEMIA THROUGH INHIBITION OF SYNTHESIS OF N-ACETYLGLUTAMATE
|
VALPROATE PLASMA LEVELS ARE INCREASED AFTER CO-ADMINISTRATION
|